163 related articles for article (PubMed ID: 21561702)
1. Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: role of myocyte structure and myocardial perfusion.
Vaillant F; Dehina L; Mazzadi A; Descotes J; Chevalier P; Tabib A; Bui-Xuan B; Riera C; Belhani D; Timour Q
Resuscitation; 2011 Aug; 82(8):1092-9. PubMed ID: 21561702
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study.
Vaillant F; Timour Q; Descotes J; Manati W; Belhani D; Bui-Xuan B; Tabib A; Bricca G; Chevalier P
J Cardiovasc Pharmacol; 2008 Dec; 52(6):548-54. PubMed ID: 19034029
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status.
Vaillant F; Dehina L; Dizerens N; Bui-Xuan B; Tabib A; Lauzier B; Chevalier P; Descotes J; Timour Q
Resuscitation; 2013 Mar; 84(3):384-90. PubMed ID: 22940600
[TBL] [Abstract][Full Text] [Related]
4. Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias.
Ng FS; Shadi IT; Peters NS; Lyon AR
J Mol Cell Cardiol; 2013 Jun; 59():67-75. PubMed ID: 23402927
[TBL] [Abstract][Full Text] [Related]
5. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
[TBL] [Abstract][Full Text] [Related]
6. Haemodynamic impact of the left ventricular pacing site during graded ischaemia in an open-chest pig model.
Bordachar P; Labrousse L; Thambo JB; Reant P; Lafitte S; O'Neill MD; Jais P; Haissaguerre M; Clementy J; Dos Santos P
Europace; 2008 Feb; 10(2):242-8. PubMed ID: 18256130
[TBL] [Abstract][Full Text] [Related]
7. Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart.
Palee S; Weerateerangkul P; Surinkeaw S; Chattipakorn S; Chattipakorn N
Exp Physiol; 2011 Aug; 96(8):778-89. PubMed ID: 21666037
[TBL] [Abstract][Full Text] [Related]
8. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
Aupetit JF; Loufoua-Moundanga J; Faucon G; Timour Q
Br J Pharmacol; 1997 Feb; 120(3):523-9. PubMed ID: 9031759
[TBL] [Abstract][Full Text] [Related]
9. [Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments].
Timour Q; Freysz M; Aupetit JF; Loufoua J; Frassati D; Faucon G
Bull Acad Natl Med; 1996 Jan; 180(1):215-26; discussion 226-7. PubMed ID: 8696877
[TBL] [Abstract][Full Text] [Related]
10. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart.
Ceconi C; Cargnoni A; Francolini G; Parinello G; Ferrari R
Cardiovasc Res; 2009 Oct; 84(1):72-82. PubMed ID: 19477966
[TBL] [Abstract][Full Text] [Related]
11. Disappearance with ischaemic depolarization of the antifibrillatory activity in a sodium channel blocker and appearance in calcium channel blocker.
Bui-Xuan B; Aupetit JF; Freysz M; Loufoua-Moundanga J; Faucon G; Timour Q
Arch Int Pharmacodyn Ther; 1996; 331(3):246-62. PubMed ID: 9124997
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a mouse in vitro model of ischaemia-induced ventricular fibrillation.
Stables CL; Curtis MJ
Cardiovasc Res; 2009 Jul; 83(2):397-404. PubMed ID: 19228704
[TBL] [Abstract][Full Text] [Related]
13. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
[TBL] [Abstract][Full Text] [Related]
14. Heart rate reduction during exercise-induced myocardial ischaemia and stunning.
Monnet X; Colin P; Ghaleh B; Hittinger L; Giudicelli JF; Berdeaux A
Eur Heart J; 2004 Apr; 25(7):579-86. PubMed ID: 15120055
[TBL] [Abstract][Full Text] [Related]
15. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction.
Heusch G; Skyschally A; Gres P; van Caster P; Schilawa D; Schulz R
Eur Heart J; 2008 Sep; 29(18):2265-75. PubMed ID: 18621770
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration.
Aupetit JF; Frassati D; Bui-Xuan B; Freysz M; Faucon G; Timour Q
Cardiovasc Res; 1998 Mar; 37(3):646-55. PubMed ID: 9659448
[TBL] [Abstract][Full Text] [Related]
17. The effects of isosteviol against myocardium injury induced by ischaemia-reperfusion in the isolated guinea pig heart.
Xu D; Zhang S; Foster DJ; Wang J
Clin Exp Pharmacol Physiol; 2007; 34(5-6):488-93. PubMed ID: 17439420
[TBL] [Abstract][Full Text] [Related]
18. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A
J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904
[TBL] [Abstract][Full Text] [Related]
19. Effects of transient myocardial ischemia on the ventricular defibrillation threshold.
Anastasiou-Nana MI; Tsagalou EP; Charitos C; Siafakas KX; Drakos S; Terrovitis JV; Ntalianis A; Doufas A; Mavrikakis J; Nanas JN
Pacing Clin Electrophysiol; 2005 Feb; 28(2):97-101. PubMed ID: 15679638
[TBL] [Abstract][Full Text] [Related]
20. Ventricular fibrillation induced by ischemia-reperfusion is not prevented by the NPY Y2 receptor antagonist BIIE0246.
Ilebekk A; Eriksen M; Sevre K; Aspelin T; Björkman JA; Lyberg T; Nordlander M
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):177-83. PubMed ID: 17056830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
